Edition:
India

Infinity Pharmaceuticals Inc (INFI.OQ)

INFI.OQ on NASDAQ Stock Exchange Global Select Market

2.05USD
22 Jun 2018
Change (% chg)

-- (--)
Prev Close
$2.05
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
117,244
52-wk High
$3.75
52-wk Low
$0.93

Chart for

About

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145,... (more)

Overall

Beta: 2.69
Market Cap(Mil.): $80.60
Shares Outstanding(Mil.): 50.69
Dividend: --
Yield (%): --

Financials

BRIEF-Infinity Pharmaceuticals Q1 Loss Per Share $0.18

* Q1 EARNINGS PER SHARE VIEW $-0.18 -- THOMSON REUTERS I/B/E/S

09 May 2018

BRIEF-Infinity Pharmaceuticals Q1 Loss Per Share $0.18

* INFINITY PHARMACEUTICALS SAYS FOR THREE MONTHS ENDED MARCH 31, 2018, DILUTED LOSS PER COMMON SHARE WAS $0.18 - SEC FILING

09 May 2018

BRIEF-Infinity Pharmaceuticals Files Prospectus Relates To Resale Of Up To 1.1 Mln Shares Of Co's Common Stock - SEC Filing

* INFINITY PHARMACEUTICALS INC FILES PROSPECTUS RELATES TO RESALE OF UP TO 1.1 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDER - SEC FILING Source text: (https://bit.ly/2HF2NcI) Further company coverage:

01 May 2018

BRIEF-BVF Partners Reports 21.7 Pct Stake In Infinity Pharmaceuticals As Of April 10

* BVF PARTNERS LP REPORTS 21.7 PCT STAKE IN INFINITY PHARMACEUTICALS INC AS OF APRIL 10 - SEC FILING

13 Apr 2018

BRIEF-Infinity Pharma Qtrly Diluted Loss Per Common Share $0.14​

* INFINITY PHARMACEUTICALS PROVIDES COMPANY UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

16 Mar 2018

BRIEF-Infinity Expects Net Loss For 2018 To Range From $40 Mln To $50 Mln​

* INFINITY PHARMACEUTICALS INC - ‍INFINITY EXPECTS NET LOSS FOR 2018 TO RANGE FROM $40 MILLION TO $50 MILLION​

08 Jan 2018

Earnings vs. Estimates